The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Nov. 12, 2024

Filed:

Mar. 08, 2024
Applicant:

Bioxcel Therapeutics, Inc., New Haven, CT (US);

Inventors:

Vasukumar Kakumanu, New Haven, CT (US);

David Christian Hanley, New Haven, CT (US);

Frank Yocca, New Haven, CT (US);

Chetan Dalpatbhai Lathia, New Haven, CT (US);

Lavanya Rajachandran, New Haven, CT (US);

Robert Risinger, New Haven, CT (US);

Assignee:

BioXcel Therapeutics, Inc., New Haven, CT (US);

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A01N 37/00 (2006.01); A01N 25/00 (2006.01); A01N 37/12 (2006.01); A01N 37/44 (2006.01); A61K 9/00 (2006.01); A61K 31/215 (2006.01); A61K 31/24 (2006.01); A61K 31/4174 (2006.01); A61K 47/38 (2006.01); A61P 25/18 (2006.01); A61P 25/20 (2006.01);
U.S. Cl.
CPC ...
A61K 31/4174 (2013.01); A61K 9/006 (2013.01); A61K 47/38 (2013.01); A61P 25/18 (2018.01); A61P 25/20 (2018.01);
Abstract

Disclosed herein are methods of administering relatively high doses of dexmedetomidine or a pharmaceutically acceptable salt thereof to a human subject, without also inducing significant sedation. The disclosed methods are particularly suitable for the treatment of agitation, especially when associated with neurodegenerative and/or neuropsychiatric diseases such as schizophrenia, bipolar illness such as bipolar disorder or mania, dementia, depression, or delirium.


Find Patent Forward Citations

Loading…